The World Health Organization warned that artificial sweeteners, used to replace sugar in a vast range of products, do not help in losing weight and can have serious health effects.
According to the United Nations health agency, a systematic review of available evidence "suggests that use of non-sugar sweeteners (NSS) does not confer any long-term benefit in reducing body fat in adults or children.
In addition, results from the review suggest that the long-term use of NSS could increase the risk of type 2 diabetes, cardiovascular diseases, and mortality in adults.
The WHO's director for nutrition and food safety, Francesco Branca, stressed that replacing ordinary sugar with artificial sweeteners "does not help with weight control in the long term".
He added that NSS are not essential dietary factors and have no nutritional value.
The WHO said its new recommendation applied to everyone except individuals with pre-existing diabetes.
It includes all synthetic and naturally occurring or modified sweeteners not classified as sugars found in manufactured foods and beverages or sold on their own to be added to products by consumers.
Among the most widely used sweeteners are acesulfame K, aspartame, advantame, cyclamates, neotame, saccharin, sucralose, stevia, and stevia derivatives, it said.


SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test
Gold Falls Below $4,000 as Strong Dollar and Fed Rate Hike Expectations Weigh on Prices
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review
U.S. Dollar Reaches One-Year High as Tech Sell-Off and Fed Rate Hike Expectations Support Demand
Italy Investigates Microsoft Over Microsoft 365 AI Subscription Price Hike
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates
NIH Infectious Disease Leadership Shake-Up Raises Concerns Amid Ebola, Hantavirus Outbreaks
US Tightens Ebola Controls as Congo Outbreak Sparks Global Concern
Supreme Court Blocks 5th Circuit Ruling on Abortion Pill Access
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices
RFK Jr. Faces Scrutiny Over David Geier’s HHS Role and Vaccine Review Work
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales
Medicare to Cover GLP-1 Weight-Loss and Diabetes Drugs Starting July 1
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 



